COMPANY

Likarda

HQ: Kansas City, MO source · likarda.com ↗ · Midwest

We provide enabling technologies for small molecules, biologics and cell therapies using our proprietary Core-Shell Spherification® (CSS®) encapsulation platform. Our patented CSS® encapsulation technology surrounds cells or therapeutics in customizable hydrogel matrices designed to provide protection, localization, and controlled or sustained delivery. From company website Source · Oct 13, 2026

Keywords: small molecules cell therapies biologics therapeutics

Location: Kansas City, MO · source · Oct 15, 2026

Profile checked Oct 10, 2026

1NIH grants

Timeline

Jul 28, 2026 Grant Government grant announced Jul 28, 2026. Source: company's own press page. source ↗
Apr 7, 2026 Partnership Partnership / licensing announced Apr 7, 2026. Source: company's own press page. source ↗
Jun 9, 2025 Partnership Partnership / licensing announced Jun 9, 2025. Source: company's own press page. source ↗

Funding

Last 2 years.

Apr 7, 2026 Partnership / licensing announced Apr 7, 2026. Source: company's own press page. source ↗
Jun 9, 2025 Partnership / licensing announced Jun 9, 2025. Source: company's own press page. source ↗
Jul 28, 2026 Government grant announced Jul 28, 2026. Source: company's own press page. source ↗

NIH awards 1

Annual award amounts. Total $256K.

Sep 7, 2021 NIH award 1R43DK130698-01 FY2021: $256,338 awarded for that fiscal year; activity R43 (SBIR); PI STEHNO-BITTEL, LISA A.; recipient as written: LIKARDA, LLC, Kansas City, MO. Clinical grade insulin-producing iPSCs enc source ↗

Connect

See your connections at Likarda on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-04